Karyopharm Therapeutics, Inc. (KPTI)

Add to research

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance
Add to research

Current Price

as of Mar 12, 2025

$7.53

P/E Ratio

N/A

Market Cap

$63.37M

Mar 19, 2024Apr 23, 2024May 29, 2024Jul 2, 2024Aug 2, 2024Sep 5, 2024Oct 8, 2024Nov 11, 2024Dec 17, 2024Jan 24, 2025Mar 12, 2025$70.00$80.00$90.00$100.00$110.00$120.00
  • EXPO
Description
Add to research

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A, Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008, and is headquartered in Newton, MA.

Metrics
Add to research

Overview

  • HQNewton, MA
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerKPTI
  • Price$7.53+1.21%

Trading Information

  • Market cap$63.37M
  • Float93.25%
  • Average Daily Volume (1m)660,816
  • Average Daily Volume (3m)853,733
  • EPS-$9.41

Company

  • Revenue$145.24M
  • Rev growth (1yr)-0.55%
  • Net income-$76.42M
  • Gross margin95.63%
  • EBITDA margin-82.01%
  • EBITDA-$119.10M
  • EV$168.20M
  • EV/Revenue1.16
  • P/EN/A
  • P/S0.42
  • P/BN/A
  • Debt/EquityN/A
Documents
Add to research
SEC Filings
8-K (2025-02-24)
8-K (2025-02-19)
8-K (2025-01-31)
8-K (2025-01-30)
8-K (2025-01-13)
8-K (2025-01-02)
8-K (2024-12-03)
8-K (2024-11-20)
8-K (2024-11-08)
8-K (2024-11-05)
8-K (2024-10-31)
8-K (2024-09-17)
8-K (2024-08-29)
8-K (2024-08-06)
8-K (2024-05-31)
8-K (2024-05-14)
8-K (2024-05-08)
8-K (2024-02-29)
8-K (2024-02-20)
8-K (2024-01-08)
8-K (2023-12-12)
8-K (2023-12-08)
8-K (2023-11-02)
8-K (2023-09-01)
8-K (2023-08-02)
8-K (2023-05-25)
8-K (2023-05-04)
8-K (2023-03-10)
8-K (2023-02-15)
8-K (2023-01-09)
10-Q (2024-11-05)
10-Q (2024-08-06)
10-Q (2024-05-08)
10-Q (2023-11-02)
10-Q (2023-08-02)
10-Q (2023-05-04)
10-K (2025-02-19)
10-K (2024-02-29)
10-K (2023-02-17)
Earnings Calls
Earnings Report 2024Q4
Earnings Report 2024Q3
Earnings Report 2024Q1
Earnings Report (2023-11-02)
Earnings Report (2023-08-02)
Factset Street Account
StreetAccount Earnings Call Q&A Summary: Karyopharm Therapeutics Q3 ($ 0.78, -0.01) (2023-11-02T15:58:14Z)
Karyopharm Therapeutics reports Q3 EPS ($0.30) vs FactSet ($0.28) [10 est, ($0.32)-(0.23)] ($0.79, 0.00) (2023-11-02T11:34:41Z)
Karyopharm reports new preliminary data in selinexor-treated patients with advanced or recurrent TP53 wild-type endometrial cancer ($0.89, 0.00) (2023-11-06T12:03:15Z)
Karyopharm announces clinical trial collaboration with Bristol Myers Squibb (BMY) to evaluate novel CELMoD agent CC- 92480 Mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma ($0.82, 0.00) (2023-10-30T12:06:33Z)